CEO: Genmab sustainable, profitable before 2017
Following a number of demanding years, which have led to a 70 % reduction of staff, Genmab is on the verge of becoming sustainable and profitable. The company has learned its lesson from past partnerships that proved too challenging for them, says the CEO.
by Benjamin Werner Christensen
A number of highly attractive partnerships with pharmaceutical giants like Johnson & Johnson, GlaxoSmithKline (GSK) and Roche, combined with annual costs of just 100m dollars, has enabled Genmab to move extremely close to becoming sustainable and profitable.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
Genmab technology to put pressure on copyists
For abonnenter
Genmab to expand Arzerra
For abonnenter
.jpg&w=384&q=75)
